MX2021000047A - Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma. - Google Patents

Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.

Info

Publication number
MX2021000047A
MX2021000047A MX2021000047A MX2021000047A MX2021000047A MX 2021000047 A MX2021000047 A MX 2021000047A MX 2021000047 A MX2021000047 A MX 2021000047A MX 2021000047 A MX2021000047 A MX 2021000047A MX 2021000047 A MX2021000047 A MX 2021000047A
Authority
MX
Mexico
Prior art keywords
methods
fusion protein
variant fusion
1bbl variant
variant
Prior art date
Application number
MX2021000047A
Other languages
English (en)
Inventor
Iris Pecker
Itai Bloch
Original Assignee
Kahr Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kahr Medical Ltd filed Critical Kahr Medical Ltd
Publication of MX2021000047A publication Critical patent/MX2021000047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan proteínas de fusión variantes de PD1-4-1BBL. También se proporcionan polipéptidos aislados que comprenden una variante de PD1 o una variante de 4-1BBL. También se proporcionan polinucleótidos y construcciones de ácido nucleico que codifican la proteína de fusión PD1-4-1BBL o el polipéptido aislado, células huésped que expresan el mismo y procedimientos de uso del mismo.
MX2021000047A 2018-07-11 2019-07-11 Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma. MX2021000047A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696365P 2018-07-11 2018-07-11
US201862786599P 2018-12-31 2018-12-31
PCT/IL2019/050782 WO2020012485A1 (en) 2018-07-11 2019-07-11 Pd1-4-1bbl variant fusion protein and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021000047A true MX2021000047A (es) 2021-05-12

Family

ID=69142114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000047A MX2021000047A (es) 2018-07-11 2019-07-11 Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.

Country Status (12)

Country Link
US (1) US20210284711A1 (es)
EP (1) EP3820887A4 (es)
JP (1) JP2021531265A (es)
KR (1) KR20210044221A (es)
CN (1) CN112543767B (es)
AU (1) AU2019301315A1 (es)
BR (1) BR112021000347A2 (es)
CA (1) CA3104778A1 (es)
IL (1) IL280102A (es)
MX (1) MX2021000047A (es)
SG (1) SG11202013170RA (es)
WO (1) WO2020012485A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
DK3565579T3 (da) * 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
KR102171766B1 (ko) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 Pd-l1 결합력이 증대된 pd-1 변이체
KR20220044284A (ko) * 2019-07-11 2022-04-07 카 메디컬 리미티드 이종이량체 및 이의 사용방법
US20230048719A1 (en) * 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US20230048361A1 (en) * 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
KR20220061644A (ko) * 2020-11-06 2022-05-13 주식회사 제넨바이오 Pd-l1 및 il-10의 융합단백질을 유효성분으로 하는 이식거부반응 치료용 약학적 조성물
CN114369581B (zh) * 2021-12-30 2023-10-20 杭州医学院 一种具有抗肿瘤免疫功能重组腺病毒、制备方法及应用
CN114940710B (zh) * 2022-06-07 2023-09-26 恺佧生物科技(上海)有限公司 一种提高重组人psma蛋白表达的方法
WO2024088404A1 (en) * 2022-10-28 2024-05-02 Fbd Biologics Limited Engineered 4-1bbl variants and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
IL300733A (en) * 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeting immune modulation
PT3177640T (pt) * 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
RS61870B1 (sr) * 2014-11-14 2021-06-30 Hoffmann La Roche Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije
MA47137B1 (fr) * 2015-07-30 2021-08-31 Macrogenics Inc Molécules de liaison pd-1 et lag-3 et leurs procédés d'utilisation
SG10201913597VA (en) * 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
CA3017036A1 (en) * 2016-03-23 2017-09-28 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Fusion proteins of pd-1 and 4-1bb
DK3565579T3 (da) * 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf

Also Published As

Publication number Publication date
US20210284711A1 (en) 2021-09-16
EP3820887A1 (en) 2021-05-19
EP3820887A4 (en) 2022-04-20
KR20210044221A (ko) 2021-04-22
IL280102A (en) 2021-03-01
CN112543767A (zh) 2021-03-23
WO2020012485A1 (en) 2020-01-16
BR112021000347A2 (pt) 2021-04-13
AU2019301315A1 (en) 2021-02-11
CA3104778A1 (en) 2020-01-16
CN112543767B (zh) 2024-05-31
SG11202013170RA (en) 2021-01-28
JP2021531265A (ja) 2021-11-18
WO2020012485A9 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2017151818A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017151940A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
EP3775192A4 (en) POLYPEPTIDE CONSTRUCTS WITH LYSINE ANTIMICROBIAL PEPTIDES (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREOF AND USES THEREOF
MY189425A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
IL276469A (en) Non-viral DNA vectors and their uses for the production of antibody and fusion protein
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
SG10201805924PA (en) Factor viii chimeric proteins and uses thereof
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
PH12021550885A1 (en) Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
EP3840771A4 (en) ANTIMICROBIAL LYSINE-PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTIONS, LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEM AND THEIR USES
DK1798240T3 (da) Rekombinante triplex scaffold-baserede polypeptider
WO2015140638A8 (en) Glycosylated vegf decoy receptor fusion protein
WO2020117778A3 (en) Reagents and methods for controlling protein function and interaction
EP3626747A4 (en) NEW RECOMBINANT BIFUNCTIONAL FUSION PROTEIN, PROCESS OF PREPARATION AND USE
MXPA05009913A (es) Proteina enlazadora del receptor nogo.
AU2021214163A1 (en) Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
IL290715A (en) nkg2d fusion proteins and their use
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.